Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Can a supplement combo boost strength and brain power in seniors?

NCT ID NCT07534878

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a multi-ingredient nutraceutical kit in 23 older adults (ages 50-80) with mild age-related decline. The goal was to see if it could improve muscle function, thinking skills, and immune health. Participants took the supplement and were measured on walking distance, strength, and cognitive tests. The study provides early evidence on safety and potential benefits for healthy aging.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

23 people

The number who actually took part.

Started

Dec 2025

Finished

Mar 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

50 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Generally healthy participants with a life expectancy ≥ 5 years * Male and female participants aged 50 to 80 years * Body Mass Index (BMI) between 25 to 35 kg/m² * Health not severely compromised (no life-threatening illness or disability) Participants with: * Intrinsic Capacity score showing mild to moderate decline * Short Physical Performance Battery (SPPB) score between 9 to 11 * Montreal Cognitive Assessment (MoCA) score \> 20 and ≤ 25 * Participants with or without comorbidities; if present, must be on a stable treatment regimen (same drug and dose) for at least 12 weeks prior to screening * Able and willing to: * Provide written informed consent * Comply with study protocol requirements * Read and write in English Exclusion Criteria: * Severe or uncontrolled chronic diseases (e.g., severe osteoarthritis, advanced cardiovascular disease, kidney failure, uncontrolled diabetes, severe COPD, terminal cancer) * Physical disability requiring a walker or wheelchair * Diagnosed dementia or cognitive impairment preventing protocol compliance * Acute infection or illness within 3 months prior to enrollment * Unstable medical conditions (e.g., recent myocardial infarction, unstable angina, uncontrolled hypertension) * Major surgery within the past 6 months or planned during the study * Severe psychiatric disorders unless well controlled * Substance abuse within the past 6 months * Participation in another clinical trial within the last 6 months * Known allergy to any component of the nutraceutical kit * Sedentary individuals unable or not advised to undergo resistance training as per protocol * Clinically relevant macro- or micronutrient deficiency (as per investigator discretion) * Pregnant or lactating women * Women of childbearing potential not using adequate contraception or with a positive urine pregnancy test * Current use of herbal products, nutraceuticals, Ayurvedic formulations, dietary supplements, or vitamin/mineral supplements and unwilling to discontinue during the study * Any other condition or abnormal laboratory finding that, in the investigator's opinion, may interfere with study results or participant safety

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Age-related functional decline are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Cognitive Dysfunction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Gplife Healthcare Private Limited

    Surat, Gujarat, 395010, India

More trials for these conditions

Other studies related to the condition(s) this trial covers.